SIMULTANEOUS ESTIMATION OF AZILSARTAN AND CILNIDIPINE IN BULK BY RP-HPLC AND ASSESSMENT OF ITS APPLICABILITY IN MARKETED TABLET DOSAGE FORM

SWATI M. ANDHALE; ANNA PRATIMA G. NIKALJE

doi:10.22159/ijap.2022v14i1.42208

Authors

SWATI M. ANDHALE Y. B. Chavan College of Pharmacy, Rauza Bag, Aurangabad 431001, MS, India
ANNA PRATIMA G. NIKALJE Wilson College, Chowpatty Seaface Road, Mumbai 400007, MS, India

DOI:

https://doi.org/10.22159/ijap.2022v14i1.42208

Keywords:

Azilsartan, Cilnidipine, RP-HPLC, Linearity and range, Precision

Abstract

Objective: This study aims to build up the RP-HPLC process for Azilsartan and Cilnidipine and authenticate the RP-HPLC process according to ICH validation code Q2R1.

Methods: System suitability testing was performed to discover the qualifying criterion of the method by injecting the identical standard solution of Azilsartan 40μg/ml and Cilnidipine 10μg/ml in mixture/combination in subsequent optimized chromatographic conditions and the chromatogram was recorded. Moreover, the planned method was validated as per ICH guideline Q2R1 for the following parameters: linearity and range, precision, accuracy, robustness, and determined % recovery.

Results: The outcomes of %RSD for retention time and peak area were found to be 0.65 and 1.32 for Azilsartan and 0.85 and 1.90 for Cilnidipine. The correlation coefficient, y-intercept, slope of the regression line were 0.9996,-1127.1, 3313.9, and 0.9993, 1460.2, 2876.4 for Azilsartan and Cilnidipine, respectively. Moreover, the range of this method was observed to be 40-240μg/ml and 10-60 μg/ml for Azilsartan and Cilnidipine, standard concentrations respectively. The % RSD achieved for precision (repeatability) was observed in the range of 1.57 to 2.43 for Azilsartan and 0.70 to 1.88 for Cilnidipine. The % accuracy was found in the range of 96.96 to 101.92% w/w for Azilsartan and 99.19 to101.96%w/w for Cilnidipine. The percent recovery values achieved for Azilsartan were in the range of 99.87 to 106.39% w/w and for Cilnidipine in the range of 94.51 to 105.96% w/w.

Conclusion: The author concludes that the simultaneous estimation of Azilsartan and Cilnidipine with predefined objectives was successfully achieved. Moreover, the method was found to be steadfast for the quantification of Azilsartan and Cilnidipine in marketed tablet dosage forms.

Downloads

Download data is not yet available.

References

Sanjay Kumar D, Harish Kumar DR. Importance of RP-HPLC in analytical method development: a review. IJPSR. 2012;3(12):4626-33.

Ravi Sankar P, Sai Snehalatha K, Shaik TF, Srinivasa Babu P. Applications of HPLC in pharmaceutical analysis. Int J Pharm Sci Rev Res 2019;59(1):117-24.

Sohni SK, Kumar R, Akhtar M, Ranjan C, Chawla G. Development and validation of RP-HPLC method for simultaneous estimation of azilsartan medoximil and chlorthalidone in bulk form and formulation using quality by design. Int J Pharm Sci Rev Res. 2016;8(2):266-72.

Baker WL, White WB. Azilsartan medoxomil: a new angiotensin II receptor antagonist for the treatment of hypertension. Ann Pharmacother. 2011;45(12):1506-15. doi: 10.1345/aph.1Q468, PMID 22116996.

White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin-receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57(3):413-20. doi: 10.1161/hypertensionaha.110.163402, PMID 21282560.

Perry CM. Azilsartan medoxomil: a review of its use in hypertension. Clin Drug Investig. 2012;32(9):621-39. doi: 10.2165/11209600-000000000-00000, PMID 22877322.

Datar PA, Aher SB, Washimkar MH, Auti PB. 2DQSAR of novel 1, 4-dihydropyridine derivative blocking n-type-calcium channels. J Chem Pharm Res. 2012;4:1117-22.

Rupareliya RH, Joshi HS. Stability indicating simultaneous validation of telmisartan and cilnidipine with forced degradation behavior study by RP-HPLC in tablet dosage form; 2013.

Iyer RP, Lindsey ML, Chilton RJ. A two-for-one bargain: using cilnidipine to treat hypertension and its comorbidities. J Clin Hypertens (Greenwich). 2013;15(7):455-7. doi: 10.1111/jch.12112. PMID 23815532.

Takahara A, Nakamura Y, Wagatsuma H, Aritomi S, Nakayama A, Satoh Y, Akie Y, Sugiyama A. Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart. Br J Pharmacol. 2009;158(5):1366-74. doi: 10.1111/j.1476-5381.2009.00407.x, PMID 19785655.

Fujii S, Kameyama K, Hosono M, Hayashi Y, Kitamura K. Effect of cilnidipine, a novel dihydropyridine Ca++-channel antagonist, on N-type Ca++channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther. 1997;280(3):1184-91. PMID 9067302.

Hosono M, Fujii S, Hiruma T, Watanabe K, Hayashi Y, Ohnishi H, Takata Y, Kato H. Inhibitory effect of cilnidipine on vascular sympathetic neurotransmission and subsequent vasoconstriction in spontaneously hypertensive rats. Japan J Pharmacol. 1995;69(2):127-34. doi: 10.1254/jjp.69.127, PMID 8569049.

Shrinivasan R, Kamal Chandra J, Kumar R, Dushyant Kumar N. Stability indicating RP-HPLC method for determination of azilsartan medoxomil in bulk and its dosage form. IJPAR. 2014;3(4):445-52.

Masthanamma SK, Jahnavi P. Stability indicating RP-HPLC method for determination of azilsartan medoxomil in pharmaceutical dosage form. Res J Pharm Technol. 2014;7(2):168-72.

Sreenivasulu J, Venkata Ramana P, Sampath Kumar Reddy G, Nagaraju ChV, Thirumalai Rajan S, Eswaraiah S. A rapid novel HPLC method for estimation of eight related compounds in azilsartan kamedoxomil and identification of degradation compounds by using LC-MS. J Chromatogr Sci. 2015;53(9):1463-74. doi: 10.1093/chromsci/bmv039, PMID 25925084.

Naazneen S, Sridevi A. Stability-indicating RP-HPLC method for the simultaneous estimation of azilsartan medoxomil and chlorthalidone in solid dosage forms. Int J Pharm Pharm Sci. 2014;6(6):236-43.

Aher SS, Saudagar RB, Kothari H. Development and validation of RP-HPLC method for simultaneous estimation of azilsartan medoxomil and chlorthalidone in bulk and tablet dosage form. Int J Curr Pharm Sci. 2018;10(6):21-4. doi: 10.22159/ijcpr.2018v10i6.30967.

Pawar VT, Pawar SV, More HN, Kulkarni AS, Gaikwad DT. RP-HPLC method for simultaneous estimation of cilnidipine and chlorthalidone. Rese J Pharm Technol. 2017;10(11):3990-6. doi: 10.5958/0974-360X.2017.00724.7.

Satyavati D, Kumar AG, Latha MB, Madhukar A. Validated RP-HPLC method for simultaneous estimation of chlorthalidone and cilnidipine in API and tablet dosage form. J Sci Res Pharm. 2018;7(11):124-9.

Sunitha N, Marihal SC, Sravanthi SJ, Venu A, Narasimha Rao BV, Appa Rao B. Method development and validation of RP-HPLC method for the simultaneous estimation of olmesartan and cilnidipine in bulk and formulations. IJPRAS. 2015;4(3):127-35.

Araujo P. Key aspects of analytical method validation and linearity evaluation. J Chromatogr B Anal Technol Biomed Life Sci. 2009;877(23):2224-34. doi: 10.1016/j.jchromb.2008.09.030, PMID 18929516.

Lakshmi B, Reddy TV. A novel RP-HPLC method for the quantification of linagliptin in formulations. J Mol. 2012;2:155.

Joshi R, Sharma R. Development and validation of RP-HPLC method for simultaneous estimation of three-component tablet formulation containing acetaminophen, chlorzoxazone, and aceclofenac. Anal Lett. 2008;41(18):3297-308. doi: 10.1080/00032710802515086.

Vander Heyden Y, Nijhuis A, Smeyers Verbeke J, Vandeginste BG, Massart DL. Guidance for robustness/ruggedness tests in method validation. J Pharm Biomed Anal. 2001;24(5-6):723-53. doi: 10.1016/s0731-7085(00)00529-x, PMID 11248467.

Ferreira SLC, Caires AO, Borges TdS, Lima AMDS, Silva LOB, dos Santos WNL. Robustness evaluation in analytical methods optimized using experimental designs. Microchem J. 2017;131:163-9. doi: 10.1016/j.microc.2016.12.004.

Patel SN, Hinge MA, Bhanushali VM. Development and validation of a UV spectrophotometric method for simultaneous determination of cilnidipine and chlorthalidone. J Pharm Res. 2015;9:41-5.

Uhrovcik J. Strategy for determination of LOD and LOQ values--some basic aspects. Talanta. 2014;119:178-80. doi: 10.1016/j.talanta.2013.10.061, PMID 24401401.

Jain JJ, Patel SA. Development and validation of spectrophotometric method for simultaneous estimation of azilsartan kamedoxomil and cilnidipine in the synthetic mixture. World J Pharm Res. 2018;7(8):948-58.

Rao AL, Eswarudu MM, Vijay K. Bioanalytical method development and validation for simultaneous determination of chlorthalidone and cilnidipine drugs in human plasma by RP-HPLC. Int J Res Pharm Chem. 2019;9(1):33-44.

Sawaikar L, Kapupara P. Development and validation of a stability indicating RP-HPLC method for the estimation of chlorthalidone and cilnidipine in combined pharmaceutical dosage form. Res J Pharm Technol. 2020;13(5):2376-80. doi: 10.5958/0974-360X.2020.00427.8.

Aruna G, Bharathi K. Prasad, development and validation of bioanalytical HPLC method for simultaneous estimation of cilnidipine and nebivolol in human plasma. Int J Pharm Pharm Sci. 2017;9(10):253-9.

Minase AS, Dole MN, Sawant SD. Development and validation of an analytical method for simultaneous estimation of cilnidipine and olmesartan medoxomil in bulk and tablet dosage form by RP-HPLC. Int J Pharm Pharm Sci. 2014;6(7):508-11.

Vekariya PP, Joshi HS. Development and validation of RP-HPLC method for azilsartan medoxomil potassium quantitation in human plasma by solid phase extraction procedure. ISRN Spectrosc. 2013;2013:1-6. doi: 10.1155/2013/572170.

Jani RJ, Patel SA. Spectrophotometric method for simultaneous estimation of azilsartan kamedoxomil and cilnidipine in the synthetic mixture. Int J Pharm Pharm Sci. 2018;3(2):86-90.